- Home
- FEMY vs NTIP Comparison
FEMY vs NTIP Comparison
Compare FEMY & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- NTIP
- Stock Information
- Founded
- FEMY 2004
- NTIP 1990
- Country
- FEMY United States
- NTIP United States
- Employees
- FEMY N/A
- NTIP N/A
- Industry
- FEMY Medical/Dental Instruments
- NTIP Multi-Sector Companies
- Sector
- FEMY Health Care
- NTIP Miscellaneous
- Exchange
- FEMY Nasdaq
- NTIP Nasdaq
- Market Cap
- FEMY 31.9M
- NTIP 28.6M
- IPO Year
- FEMY 2021
- NTIP 1998
- Fundamental
- Price
- FEMY $0.96
- NTIP $1.25
- Analyst Decision
- FEMY Strong Buy
- NTIP
- Analyst Count
- FEMY 3
- NTIP 0
- Target Price
- FEMY $8.67
- NTIP N/A
- AVG Volume (30 Days)
- FEMY 362.3K
- NTIP 13.6K
- Earning Date
- FEMY 08-07-2025
- NTIP 08-11-2025
- Dividend Yield
- FEMY N/A
- NTIP 8.33%
- EPS Growth
- FEMY N/A
- NTIP N/A
- EPS
- FEMY N/A
- NTIP N/A
- Revenue
- FEMY $1,699,232.00
- NTIP $250,000.00
- Revenue This Year
- FEMY $231.84
- NTIP N/A
- Revenue Next Year
- FEMY $245.28
- NTIP N/A
- P/E Ratio
- FEMY N/A
- NTIP N/A
- Revenue Growth
- FEMY 61.97
- NTIP N/A
- 52 Week Low
- FEMY $0.69
- NTIP $1.16
- 52 Week High
- FEMY $1.80
- NTIP $1.78
- Technical
- Relative Strength Index (RSI)
- FEMY 48.09
- NTIP 49.11
- Support Level
- FEMY $0.91
- NTIP $1.20
- Resistance Level
- FEMY $0.95
- NTIP $1.30
- Average True Range (ATR)
- FEMY 0.06
- NTIP 0.05
- MACD
- FEMY 0.01
- NTIP -0.00
- Stochastic Oscillator
- FEMY 31.16
- NTIP 49.29
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.